Patients with glioma harbored FGFR3 fusions were reported to have responded well to FGFR inhibition, and these FGFR3 fusions have been proposed as novel therapeutic targets in glioma [45, 46]. The gene discussed is FGFR3; the disease is central nervous system cancer.